🔗 Share this article World Health Organization Raises Alert Over Acute Lack of Obesity Medications Fewer than a tenth of patients who could benefit from GLP-1 drugs including Wegovy can access them, caution the WHO as it issues its initial guidance on the medications. Considering more than one billion people worldwide currently classified as obese, it is advocating for increased and just access to this class of drugs. According to estimates, over two billion could be obese by 2030 without intervention. "Our new guidelines affirms that obesity is a chronic disease that can be addressed with thorough and ongoing treatment," stated the agency's head Tedros Adhanom Ghebreyesus. Substantial prices, constrained manufacturing, and distribution challenges are major obstacles to broad access to the jabs that can aid individuals in losing considerable weight, explains the agency. GLP-1 Therapy Scarcity Despite the current most optimistic case, the production of GLP-1 therapies might only reach approximately 100 million people – less than 10% of the global need, as stated by the WHO. The advice encourages countries and companies to increase access, through strategies like voluntary licensing. Exclusive production rights on a key compound – the main ingredient of the drug Wegovy – is scheduled to end in a number of countries in 2026. The Way Weight-Loss Jabs Function These medications imitate a biological compound to delay gastric emptying, suppress the appetite and enhance feelings of fullness so individuals consume fewer calories. People commonly begin shedding pounds within a few weeks of starting on the regular doses. Evidence suggests users may regain a significant portion a year later of discontinuing the medication, when their usual hunger return. Being carrying excess weight raises your likelihood for contracting health problems, including type 2 diabetes, cardiovascular issues, brain attack, and certain malignancies. Obesity affects people in every country and was responsible for over three and a half million fatalities worldwide in 2024, according to the WHO.
Fewer than a tenth of patients who could benefit from GLP-1 drugs including Wegovy can access them, caution the WHO as it issues its initial guidance on the medications. Considering more than one billion people worldwide currently classified as obese, it is advocating for increased and just access to this class of drugs. According to estimates, over two billion could be obese by 2030 without intervention. "Our new guidelines affirms that obesity is a chronic disease that can be addressed with thorough and ongoing treatment," stated the agency's head Tedros Adhanom Ghebreyesus. Substantial prices, constrained manufacturing, and distribution challenges are major obstacles to broad access to the jabs that can aid individuals in losing considerable weight, explains the agency. GLP-1 Therapy Scarcity Despite the current most optimistic case, the production of GLP-1 therapies might only reach approximately 100 million people – less than 10% of the global need, as stated by the WHO. The advice encourages countries and companies to increase access, through strategies like voluntary licensing. Exclusive production rights on a key compound – the main ingredient of the drug Wegovy – is scheduled to end in a number of countries in 2026. The Way Weight-Loss Jabs Function These medications imitate a biological compound to delay gastric emptying, suppress the appetite and enhance feelings of fullness so individuals consume fewer calories. People commonly begin shedding pounds within a few weeks of starting on the regular doses. Evidence suggests users may regain a significant portion a year later of discontinuing the medication, when their usual hunger return. Being carrying excess weight raises your likelihood for contracting health problems, including type 2 diabetes, cardiovascular issues, brain attack, and certain malignancies. Obesity affects people in every country and was responsible for over three and a half million fatalities worldwide in 2024, according to the WHO.